No description written yet.

Industry Biotechnology Homepage ataibeckley.com
Sector Healthcare IR page —
Tags
—
Press page —

Metrics

Valuation  
Market cap $ 1.831B
Market cap (USD) —
P/E —
PEG —
P/BV 10.38
P/S —
P/OCF -14.41
P/FCF -13.31
Dividend yield 1.6%
Turnover / mcap —
Returns  
ROE -390.4%
ROI -477.0%
ROIC -349.1%
Profit margin -16,142.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2018
Revenue 4.089M 308K 314K 233K 20.376M 0 76.117M
Net profit -660.047M -149.269M -40.224M -152.385M -167.808M -169.843M -457.828K
Free cash flow -103.576M -82.443M -84.377M -105.24M -63.419M -20.825M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2018
Share price 4.09 1.33 1.41 2.66 7.63 — 5.22
Price performance 12m 2.08 -0.06 -0.47 -0.65 — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — 354,000 667,000
↳ YoY growth +88.4%
Borrowings, current (USD) — — — 82.5M 109M 51.2M 135M
Lease liabilities (USD) — — 200,000 200,000 1.27M 1.21M 2.07M
Cash and deposits (USD) 30.1M 97.2M 362M 191M 45M 17.5M 85.3M
Intangible assets (USD) — — — — 1.77M 3.25M 2.85M
Right-of-use assets (USD) — — 200,000 200,000 1.22M 1.33M 1.85M
Net debt (borrowings + leases - cash) (USD) — — — -108M 65.4M 34.9M 52.2M
Cash flow detail
Operating cash flow (USD) — -20.8M -63.2M -104M -84.1M -82.4M -103M
Purchases of property, plant and equipment (USD) — -59,000 -173,000 -773,000 -259,000 -6,000 -901,000
Purchases of intangible assets (USD) — — — — 0.00 -83,000 0.00
Change in payables (cash effect) (USD) — 1.7M 2.3M -3.03M 2.14M -1.87M -1.7M
Share buybacks (cash effect) (USD) — — -500,000 — — — —
Interest paid (cash effect) (USD) — — 0.00 -508,000 -1.92M -2.16M -793,000
Income taxes paid (cash effect) (USD) — — 0.00 -652,000 -1.48M -411,000 -589,000
Share-based compensation (USD) — 67.2M 63.4M 42.4M 33M 25.5M 14.2M
Free cash flow (OCF - PPE - intangibles) (USD) — -20.8M -63.4M -105M -84.4M -82.5M -104M
Income detail
Research and development expense (USD) — 11.4M 48M 74.3M 2M 400,000 53.1M
↳ 5y CAGR +36.0%
Total comprehensive income (USD) — -171M -188M -171M -41.7M -149M -663M
Comprehensive income to owners (USD) — -163M -182M -166M -38M -148M -662M
Reported Nov 15, 2021 Mar 30, 2022 May 11, 2023 Mar 24, 2023 Mar 17, 2025 Mar 6, 2026 Mar 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Completion of Acquisition or Disposition of Assets.

The information set forth in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.

On the Closing Date, pursuant to the terms of the Merger Agreement, the Merger was consummated. At the Effective Time, the shares of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain customary exceptions specified in the Merger Agreement, were converted into the right to receive the Merger Consideration.

In connection with the consummation of the Merger, the Company’s equity awards were treated as follows:

• at the Effective Time, each option to purchase Common Stock granted under a Company equity incentive plan (each, a “Company Stock Option”) with a per share exercise price less than the Closing Amount that was outstanding immediately prior to the Effective Time, whether or not vested (each, a “Company Cash-Out Stock Option”), was cancelled and, in exchange therefor, the holder of such Company Cash-Out Stock Option became entitled to receive (A) an amount in cash, without interest and less applicable tax withholdings, equal to the product of (1)

AtaiBeckley Inc. — Current report on Form 8-K Bull 0 Bear 0 Routine

Submission of Matters to a Vote of Security Holders

On September 8, 2026, AtaiBeckley Inc., a Delaware corporation (“AtaiBeckley”), held a virtual special meeting of its stockholders (the “Special Meeting”) to vote on the proposals identified in the definitive proxy statement of AtaiBeckley prepared in connection with the Merger Agreement (as defined below) filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 10, 2026, which was first mailed to the AtaiBeckley stockholders on August 10, 2026.

As of the close of business on August 7, 2026, the record date for the Special Meeting, there were 370,864,669 shares of common stock, par value $0.01 per share, of AtaiBeckley (“AtaiBeckley Common Stock”) issued and outstanding and entitled to vote at the Special Meeting. At the Special Meeting, a total of 243,351,557 shares of AtaiBeckley Common Stock, representing approximately 65.6% of all of the shares of issued and outstanding AtaiBeckley Common Stock entitled to vote, were present in person (virtually) or represented by proxy at the Special Meeting and thus a quorum was present. The tables below detail the final voting results for each proposal.

1.

AtaiBeckley Inc. — Other Events Bull 0 Bear 0 Routine

As previously disclosed, AtaiBeckley Inc. (the “Company”) entered into an Agreement and Plan of Merger, dated as of July 15, 2026 (the “Merger Agreement”), with Eli Lilly and Company, an Indiana corporation (“Parent”) and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent (“Merger Sub”), pursuant to which Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Parent. Capitalized terms used herein and not otherwise defined herein have the meanings set forth in the Merger Agreement.

U.S. Antitrust Review

The applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the Merger expired at 11:59 p.m. Eastern Time on August 28, 2026.

Other Regulatory Reviews

On August 21, 2026, the Competition and Markets Authority in the United Kingdom responded to a briefing paper submitted by Parent in respect of the Merger to indicate that it had, at such time, no further questions related to the Merger.

Prompts

AtaiBeckley Inc. (ticker ATAI), listed in United States.

Company History

Date Change Detail
Jan 6, 2026 Renamed ATAI BECKLEY N.V. → ATAIBECKLEY INC.
Nov 12, 2025 Renamed atai Life Sciences Luxembourg S.A. → ATAI BECKLEY N.V.
Aug 13, 2025 Renamed ATAI LIFE SCIENCES N.V. → atai Life Sciences Luxembourg S.A.
— Re-registered Now files as AtaiBeckley Inc. (CIK 2081043), succeeding Atai Beckley N.V. (CIK 1840904). Filings under both are this company's.

ETFs Holding AtaiBeckley Inc.

ETF Weight in ETF Shares Market value As of
EVNT 1.03% 18,303 $ 134.344K Aug 31, 2026
RESM 0.07% 504 $ 2,656.08 Jun 30, 2026
MSSM 0.02% 20,013 $ 146.895K Aug 31, 2026